SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix (OCUL) is trending after announcing positive Phase 3 SOL-1 trial results for its wet AMD therapy, Axpaxli, which met the primary superiority endpoint over Eylea. The community is actively debating the stock's sharp decline despite clinical success, with discussions centered on market manipulation versus concerns about Axpaxli's commercial competitiveness against existing treatments and noted side effects.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is actively discussed following a confirmed acquisition offer from Hapag-Lloyd for $35 per share, fueling community speculation about a significant short squeeze, the payment of remaining dividends, and the complexities of regulatory approvals for a deal with an extended closing timeline.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending following the release of positive Phase 3 trial results for its COMP360 psilocybin therapy in treatment-resistant depression, demonstrating statistically significant efficacy and a favorable safety profile. The community views this as a major step towards potential FDA approval and a significant advancement in mental health treatment, positioning CMPS as a frontrunner in the emerging psychedelic therapeutics sector despite volatile price action.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending following news of an impending reverse stock split set to drastically reduce its share float, igniting fervent discussion among traders. Many view this as a strategic maneuver by management, potentially coupled with a "poison pill" defense and high cost-to-borrow, to engineer a massive short squeeze, drawing on the stock's history of extreme volatility and past rallies.

Masimo Corp. is a global technology company, which engages in the development, manufacture, and marketing of patient monitoring technologies, and automation and connectivity solutions. Its products include remote patient monitoring, connectivity, and hospital automation solutions, including Masimo Patient SafetyNet, Masimo Patient SafetyNet Surveillance, Masimo SafetyNet, Masimo SafetyNet-Open, Replica, Iris, MyView, UniView, Uniview: 60, Trace, Masimo Sleep, Centroid, and Bridge. It operates through the following segments: Healthcare and Non-Healthcare. The Healthcare segment develops, manufactures, and markets a variety of noninvasive monitoring technologies and hospital automation solutions and therapeutics. The Non-Healthcare segment designs, develops, manufactures, markets and sells a broad portfolio of premium, high-performance audio products and services. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.

Masimo Corp

Masimo is trending following the definitive announcement that Danaher will acquire the company for $180 per share in cash, representing a $9.9 billion total consideration, which the community views as a significant upside catalyst. This acquisition news comes amid a substantial patent infringement victory against Apple and past discussions driven by activist investors to streamline Masimo's business.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

Despite a significant run-up following its CFTC Designated Contract Market license approval for U.S. prediction markets, Gemini (GEMI) faces extensive community discussion regarding its substantial post-IPO decline, executive departures, and recent workforce cuts, sparking fervent debate on its long-term viability amidst crypto market volatility.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

eToro Group Ltd. engages in the development, management, and provision of online trading software solutions and services. The firm's trading platform, eToro, allows users to trade financial instruments. It also enables non-professionals to trade in markets that were previously the exclusive arena of professional investors. The company was founded by Johnathan Alexander Assia, Guy Gamzu, David Ring, and Ronen Assia on December 14, 2006 and is headquartered in Bnei Braq, Israel.

Etoro Group Ltd - Ordinary Shares - Class A

eToro Group Ltd

eToro is trending higher after reporting strong Q4 earnings that beat consensus estimates, further boosted by an expanded share repurchase program. The community is actively discussing the company's solid performance and increased buyback, with many viewing the stock as undervalued given its profitability and growth in the fintech sector.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfer (ET) is trending following its Q4 earnings, where investors are focused on robust revenue, an increased 2026 EBITDA outlook, and a higher distribution, largely overlooking an EPS miss. This midstream giant is also gaining attention for its strategic shift from the Lake Charles LNG project, signaling a stronger focus on its essential natural gas infrastructure, particularly growing demand from AI data centers.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending on news of securing an $11.5 million full-rate production contract from a key US defense prime and being selected as the first qualified additive manufacturing vendor for the U.S. Army's ground vehicle systems. The community is buzzing about its disruptive metal 3D printing technology for complex aerospace and defense parts, anticipating significant future contracts with partners like SpaceX and Anduril amidst high short interest and institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IBRX
If you have CIS + Papillary tumors (the flat cancer plus the finger-like growths), you are fully covered under the new EU authorization.
If you have Papillary-only disease (meaning no CIS is present in your pathology report), it is not technically part of the &quot;on-label&quot; indication in Europe yet.
2026 NCCN Update Matters for Europe
formal EU label mirrors the FDA&#39;s &quot;CIS-centric&quot; language, the NCCN v1.2026 updates we discussed are being used by European oncologists to bridge this gap:
European doctors often look to NCCN guidelines as the global &quot;gold standard.&quot; Since the NCCN now explicitly links CIS and papillary disease (the &quot;clonal link&quot;), a doctor in the EU can use this evidence to justify prescribing it for a papillary-only patient.
The 2026 guidelines highlight the 96% survival rate for the papillary-only cohort (Cohort B), which gives European patients a strong &quot;Right to Treat&quot; argument when negotiating with national health systems like Germany&#39;s G-BA or France&#39;s HAS.

Johann

NTyoda

Wayne

Rich rellihen

JLH1903

zaltenbairt

Elizabeth Brown

Ricardo Sande

Jon brand

StockTwits for iOS

ImmunityBio Inc


If you have CIS + Papillary tumors (the flat cancer plus the finger-like growths), you are fully covered under the new EU authorization.
If you have Papillary-only disease (meaning no CIS is present in your pathology report), it is not technically part of the "on-label" indication in Europe yet.
2026 NCCN Update Matters for Europe
formal EU label mirrors the FDA's "CIS-centric" language, the NCCN v1.2026 updates we discussed are being used by European oncologists to bridge this gap:
European doctors often look to NCCN guidelines as the global "gold standard." Since the NCCN now explicitly links CIS and papillary disease (the "clonal link"), a doctor in the EU can use this evidence to justify prescribing it for a papillary-only patient.
The 2026 guidelines highlight the 96% survival rate for the papillary-only cohort (Cohort B), which gives European patients a strong "Right to Treat" argument when negotiating with national health systems like Germany's G-BA or France's HAS.